Floatz logo

Adma3

Advanced/Metastatic Solid Tumours

Canadian Cancer Trials GroupvaccinePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced/Metastatic Solid Tumours cohort.

Asset / SponsorPhaseRating
mg1ma3
Canadian Cancer Trials Group
Phase 1/2CCC

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →